FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrilic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control

Authorized Users Only
2019
Authors
Bojanin, Dragana
Vekić, Jelena
Milenković, Tatjana
Vuković, Rade
Zeljković, Aleksandra
Stefanović, Aleksandra
Janać, Jelena
Ivanišević, Jasmina
Mitrović, Katarina
Miljković, Milica
Spasojević-Kalimanovska, Vesna
Article (Published version)
Metadata
Show full item record
Abstract
Background and aims: Dyslipidemia in type 1 diabetes mellitus (T1DM) is characterised by altered distributions of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subclasses. Recent studies suggested that proprotein convertase subtilisin/kexin 9 (PCSK9) may contribute to the development of dyslipidemia in T1DM. In this cross-sectional study, we investigated the association between PCSK9 and lipoprotein subclasses in young T1DM patients, with respect to glycemic control. Methods: Plasma PCSK9 and lipoprotein subclasses were determined in 207 patients with T1DM (106 boys and 101 girls), aged 13.9 +/- 3.0 years and treated by intensive insulin therapy. Results: Plasma PCSK9 levels significantly increased with worsening of glycemic control (p lt 0.001). T1DM patients with poor glucoregulation had the highest proportion of small, dense LDL (sdLDL) and smaller HDL particles, as well. PCSK9 was positively associated with markers of glucose homeostasis and serum lipid paramet...ers only in patients with suboptimal/poor glucoregulation. In well-controlled T1DM, plasma PCSK9 level was inversely associated with a relative proportion of sdLDL particles (p lt 0.01) and this association remained significant in multivariate analysis. In T1DM patients with suboptimal/poor glycemic control, PCSK9 was positively associated with the proportion of the smallest HDL3c particles (p lt 0.001), but negatively with HDL size (p lt 0.05). Conclusions: The extent of achieved metabolic control modifies the association between PCSK9 and lipoprotein subclasses in T1DM. Further investigations are needed to reveal whether the observed effects of glycemic control on PCSK9 and sdLDL levels have causal consequences on CVD risk in young patients with T1DM.

Keywords:
PCSK9 / Small / Dense LDL / HDL / Glucoregulation / Dyslipidemia / Type 1 diabetes
Source:
Atherosclerosis, 2019, 280, 14-20
Publisher:
  • Elsevier Ireland Ltd, Clare
Projects:
  • Interactive role of dyslipidemia, oxidative stress and inflammation in atherosclerosis and other diseases: genetic and biochemical markers (RS-175035)

DOI: 10.1016/j.atherosclerosis.2018.11.020

ISSN: 0021-9150

PubMed: 30453116

WoS: 000456421100003

Scopus: 2-s2.0-85056660723
[ Google Scholar ]
9
10
URI
http://farfar.pharmacy.bg.ac.rs/handle/123456789/3326
Collections
  • Radovi istraživača / Researchers’ publications
Institution
Pharmacy
TY  - JOUR
AU  - Bojanin, Dragana
AU  - Vekić, Jelena
AU  - Milenković, Tatjana
AU  - Vuković, Rade
AU  - Zeljković, Aleksandra
AU  - Stefanović, Aleksandra
AU  - Janać, Jelena
AU  - Ivanišević, Jasmina
AU  - Mitrović, Katarina
AU  - Miljković, Milica
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2019
UR  - http://farfar.pharmacy.bg.ac.rs/handle/123456789/3326
AB  - Background and aims: Dyslipidemia in type 1 diabetes mellitus (T1DM) is characterised by altered distributions of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subclasses. Recent studies suggested that proprotein convertase subtilisin/kexin 9 (PCSK9) may contribute to the development of dyslipidemia in T1DM. In this cross-sectional study, we investigated the association between PCSK9 and lipoprotein subclasses in young T1DM patients, with respect to glycemic control. Methods: Plasma PCSK9 and lipoprotein subclasses were determined in 207 patients with T1DM (106 boys and 101 girls), aged 13.9 +/- 3.0 years and treated by intensive insulin therapy. Results: Plasma PCSK9 levels significantly increased with worsening of glycemic control (p  lt  0.001). T1DM patients with poor glucoregulation had the highest proportion of small, dense LDL (sdLDL) and smaller HDL particles, as well. PCSK9 was positively associated with markers of glucose homeostasis and serum lipid parameters only in patients with suboptimal/poor glucoregulation. In well-controlled T1DM, plasma PCSK9 level was inversely associated with a relative proportion of sdLDL particles (p  lt  0.01) and this association remained significant in multivariate analysis. In T1DM patients with suboptimal/poor glycemic control, PCSK9 was positively associated with the proportion of the smallest HDL3c particles (p  lt  0.001), but negatively with HDL size (p  lt  0.05). Conclusions: The extent of achieved metabolic control modifies the association between PCSK9 and lipoprotein subclasses in T1DM. Further investigations are needed to reveal whether the observed effects of glycemic control on PCSK9 and sdLDL levels have causal consequences on CVD risk in young patients with T1DM.
PB  - Elsevier Ireland Ltd, Clare
T2  - Atherosclerosis
T1  - Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control
VL  - 280
SP  - 14
EP  - 20
DO  - 10.1016/j.atherosclerosis.2018.11.020
ER  - 
@article{
author = "Bojanin, Dragana and Vekić, Jelena and Milenković, Tatjana and Vuković, Rade and Zeljković, Aleksandra and Stefanović, Aleksandra and Janać, Jelena and Ivanišević, Jasmina and Mitrović, Katarina and Miljković, Milica and Spasojević-Kalimanovska, Vesna",
year = "2019",
url = "http://farfar.pharmacy.bg.ac.rs/handle/123456789/3326",
abstract = "Background and aims: Dyslipidemia in type 1 diabetes mellitus (T1DM) is characterised by altered distributions of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subclasses. Recent studies suggested that proprotein convertase subtilisin/kexin 9 (PCSK9) may contribute to the development of dyslipidemia in T1DM. In this cross-sectional study, we investigated the association between PCSK9 and lipoprotein subclasses in young T1DM patients, with respect to glycemic control. Methods: Plasma PCSK9 and lipoprotein subclasses were determined in 207 patients with T1DM (106 boys and 101 girls), aged 13.9 +/- 3.0 years and treated by intensive insulin therapy. Results: Plasma PCSK9 levels significantly increased with worsening of glycemic control (p  lt  0.001). T1DM patients with poor glucoregulation had the highest proportion of small, dense LDL (sdLDL) and smaller HDL particles, as well. PCSK9 was positively associated with markers of glucose homeostasis and serum lipid parameters only in patients with suboptimal/poor glucoregulation. In well-controlled T1DM, plasma PCSK9 level was inversely associated with a relative proportion of sdLDL particles (p  lt  0.01) and this association remained significant in multivariate analysis. In T1DM patients with suboptimal/poor glycemic control, PCSK9 was positively associated with the proportion of the smallest HDL3c particles (p  lt  0.001), but negatively with HDL size (p  lt  0.05). Conclusions: The extent of achieved metabolic control modifies the association between PCSK9 and lipoprotein subclasses in T1DM. Further investigations are needed to reveal whether the observed effects of glycemic control on PCSK9 and sdLDL levels have causal consequences on CVD risk in young patients with T1DM.",
publisher = "Elsevier Ireland Ltd, Clare",
journal = "Atherosclerosis",
title = "Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control",
volume = "280",
pages = "14-20",
doi = "10.1016/j.atherosclerosis.2018.11.020"
}
Bojanin D, Vekić J, Milenković T, Vuković R, Zeljković A, Stefanović A, Janać J, Ivanišević J, Mitrović K, Miljković M, Spasojević-Kalimanovska V. Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control. Atherosclerosis. 2019;280:14-20
Bojanin, D., Vekić, J., Milenković, T., Vuković, R., Zeljković, A., Stefanović, A., Janać, J., Ivanišević, J., Mitrović, K., Miljković, M.,& Spasojević-Kalimanovska, V. (2019). Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control.
AtherosclerosisElsevier Ireland Ltd, Clare., 280, 14-20.
https://doi.org/10.1016/j.atherosclerosis.2018.11.020
Bojanin Dragana, Vekić Jelena, Milenković Tatjana, Vuković Rade, Zeljković Aleksandra, Stefanović Aleksandra, Janać Jelena, Ivanišević Jasmina, Mitrović Katarina, Miljković Milica, Spasojević-Kalimanovska Vesna, "Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control" 280 (2019):14-20,
https://doi.org/10.1016/j.atherosclerosis.2018.11.020 .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceInstitutionsAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB